NOTTINGHAM, England, March 14, 2023 /PRNewswire/ -- Albumedix Ltd ('Albumedix'), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed's HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing.
Sartorius completes acquisition of Albumedix
Sartorius to acquire Albumedix, for £415 million
NOTTINGHAM, England, April 14, 2022 /PRNewswire/ -- Valneva's inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14th. This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin® rHA products in the manufacturing process and final formulation of critical vaccines.